Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct;134(4):807-813.
doi: 10.1097/AOG.0000000000003452.

Relationship Between Etonogestrel Concentrations and Bleeding Patterns in Contraceptive Implant Users

Affiliations

Relationship Between Etonogestrel Concentrations and Bleeding Patterns in Contraceptive Implant Users

Aaron Lazorwitz et al. Obstet Gynecol. 2019 Oct.

Abstract

Objective: To estimate whether serum etonogestrel concentrations influence bleeding patterns and related side effects in contraceptive implant users.

Methods: We conducted a prospective cross-sectional study with healthy, reproductive-aged women using etonogestrel implants for 12-36 months. Participants completed a brief questionnaire to assess their current bleeding pattern and any experience of abnormal bleeding with the implant. We then measured serum etonogestrel concentrations. We also reviewed the charts of participants to determine whether a prescription for oral contraceptive pills was ever given for treatment of implant-related bothersome bleeding. We performed multivariable logistic regression to test for associations between serum etonogestrel concentrations and both bleeding patterns and related side effects.

Results: We enrolled 350 women, and 59.4% reported having experienced abnormal bleeding with the contraceptive implant. Only 14.9% of participants reported amenorrhea and 37.7% reported monthly periods. Among participants with reviewable medical records (n=253), roughly 20% had received a prescription for oral contraceptive pills during implant use. Increasing serum etonogestrel concentrations were significantly associated with increasing odds of reporting abnormal bleeding (adjusted odds ratio [aOR] 1.005, P=.015) and increasing odds of having received an oral contraceptive pill prescription (aOR 1.008, P=.002). For every 100 pg/mL increase in serum etonogestrel concentration, contraceptive implant users in this study had 1.6 times the odds of reporting abnormal bleeding and 2.3 times the odds of having received a prescription as treatment for bothersome bleeding.

Conclusion: We found both objective and subjective evidence that higher levels of progestin from the contraceptive implant were associated with bleeding side effects experienced by women in this study. Pharmacologic variation may influence the side effects women experience with a variety of hormonal contraceptive methods, in turn affecting patient satisfaction and discontinuation rates.

PubMed Disclaimer

Conflict of interest statement

Financial Disclosure

Dr. Teal has served on scientific advisory boards of Allergan and Bayer Healthcare, and serves on a Data Monitoring Board for a study funded by Merck and Co. Dr. Teal and Dr. Lazorwitz receive research funding from Merck and Co. for an investigator-initiated study on drug–drug interactions with the etonogestrel contraceptive implant. The University of Colorado Department of Obstetrics and Gynecology has received research funding from Bayer, Agile Therapeutics, Merck and Co, and Medicines360. The other authors did not report any potential conflicts of interest.

Similar articles

Cited by

References

    1. Daniels K, Daugherty J, Jones J. Current contraceptive status among women aged 15–44: United States, 2011–2013. NCHS data brief 2014. December(173):1–8. - PubMed
    1. Daniels K, Mosher WD. Contraceptive methods women have ever used: United States, 1982–2010. National health statistics reports 2013. February 14(62):1–15. - PubMed
    1. Apter D, Briggs P, Tuppurainen M, Grunert J, Lukkari-Lax E, Rybowski S, et al. A 12-month multicenter, randomized study comparing the levonorgestrel intrauterine system with the etonogestrel subdermal implant. Fertil Steril 2016. July;106(1):151–7.e5. - PubMed
    1. Hatcher RA, Trussell J, Stewart F, Nelson A, Cates W, Guest F, et al. Contraceptive technology. New York: Ardent Media: Inc; 2011.
    1. Mansour D, Korver T, Marintcheva-Petrova M, Fraser IS. The effects of Implanon on menstrual bleeding patterns. Eur J Contracept Reprod Health Care 2008. June;13 Suppl 1:13–28. - PubMed

Publication types

MeSH terms